KYTX · NASDAQ
Kyverna Therapeutics (KYTX) Stock Price & Fundamentals
Kyverna Therapeutics (KYTX) closed at $638.41 on Oct 9, 2026, down 0.24% from the previous close of $639.97.
Share price, past year
1Y +4.68%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $638.41 |
| Sep 30, 2026 | $612.36 |
| Aug 31, 2026 | $616.91 |
| Jul 31, 2026 | $643.74 |
| Jun 30, 2026 | $610.27 |
| May 29, 2026 | $574.55 |
| Apr 30, 2026 | $571.14 |
| Mar 31, 2026 | $590.01 |
| Feb 27, 2026 | $617.24 |
| Jan 30, 2026 | $605.63 |
| Dec 31, 2025 | $594.72 |
| Nov 28, 2025 | $594.95 |
| Oct 31, 2025 | $587.15 |
Key statistics
- Market cap
- $39.31B
- EPS (TTM)
- −$2.93
- Net income (TTM)
- −$152.64M
- Shares outstanding
- 61.6M
- 52-week range
- $554.60 – $648.64
Kyverna Therapeutics's market cap is $39.31B, based on a share price of $638.41 and 61.6M shares outstanding as of Jun 30, 2026.
Financials
Kyverna Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Kyverna Therapeutics reported a net loss of $161.31M in fiscal 2025.
Company profile
- Name
- Kyverna Therapeutics, Inc.
- Ticker
- KYTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 5980 Horton Street, Suite 200, Emeryville, CA
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001994702
Recent SEC filings
- Sep 24, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jul 27, 2026
- Jul 9, 2026
- Jun 2, 2026
- May 18, 2026
- May 12, 2026
Frequently asked questions
What is Kyverna Therapeutics's stock price?
Kyverna Therapeutics (KYTX) closed at $638.41 on Oct 9, 2026, down 0.24% from the previous close of $639.97.
What is Kyverna Therapeutics's market cap?
Kyverna Therapeutics's market cap is $39.31B, based on a share price of $638.41 and 61.6M shares outstanding as of Jun 30, 2026.
Does Kyverna Therapeutics pay a dividend?
Kyverna Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Kyverna Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures